Agios Pharmaceuticals (AGIO) Is Down 6.3% After UAE Clears PYRUKYND As First Thalassemia Drug

Simply Wall St.03-04

Agios Pharmaceuticals recently announced that the Emirates Drug Establishment in the UAE approved PYRUKYND (mitapivat) as the first and only medicine for adult patients with non-transfusion-dependent ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616539224?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-04 18:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616539224","market":"us","top_or_hot":-1,"title":"Agios Pharmaceuticals (AGIO) Is Down 6.3% After UAE Clears PYRUKYND As First Thalassemia Drug","media":"Simply Wall St.","content":"<div>\n<p>Agios Pharmaceuticals recently announced that the Emirates Drug Establishment in the UAE approved PYRUKYND (mitapivat) as the first and only medicine for adult patients with non-transfusion-dependent ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-is-down-63-after-uae-clears-pyruk\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agios Pharmaceuticals (AGIO) Is Down 6.3% After UAE Clears PYRUKYND As First Thalassemia Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgios Pharmaceuticals (AGIO) Is Down 6.3% After UAE Clears PYRUKYND As First Thalassemia Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-04 18:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-is-down-63-after-uae-clears-pyruk><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Agios Pharmaceuticals recently announced that the Emirates Drug Establishment in the UAE approved PYRUKYND (mitapivat) as the first and only medicine for adult patients with non-transfusion-dependent ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-is-down-63-after-uae-clears-pyruk\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-is-down-63-after-uae-clears-pyruk","article_id":"2616539224","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-agio/agios-pharmaceuticals/news/agios-pharmaceuticals-agio-is-down-63-after-uae-clears-pyruk","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616539224","pubTimestamp":1772620546,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Agios Pharmaceuticals recently announced that the Emirates Drug Establishment in the UAE approved PYRUKYND (mitapivat) as the first and only medicine for adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia.\nThis approval, supported by global Phase 3 ENERGIZE and ENERGIZE-T data and backed by a regional partnership with NewBridge Pharmaceuticals, strengthens Agios’s push into Gulf markets for rare blood disorder treatments.\nNext, we’ll examine...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","UAE":"iShares MSCI UAE ETF","AGIO":"Agios Pharmaceuticals, Inc."},"translate_title":"阿联酋批准PYRUKYND为首个地中海贫血药物后，Agios Pharmaceuticals(AGIO)股价下跌6.3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UAE":1.5,"AGIO":1.5},"content_text":"Agios Pharmaceuticals recently announced that the Emirates Drug Establishment in the UAE approved PYRUKYND (mitapivat) as the first and only medicine for adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. This approval, supported by global Phase 3 ENERGIZE and ENERGIZE-T data and backed by a regional partnership with NewBridge Pharmaceuticals, strengthens Agios’s push into Gulf markets for rare blood disorder treatments. Next, we’ll examine how PYRUKYND’s UAE approval as the sole thalassemia treatment may influence Agios’s rare disease growth narrative. Uncover the next big thing with 32 elite penny stocks that balance risk and reward.AdvertisementAgios Pharmaceuticals Investment Narrative RecapTo own Agios, you need to believe that PYRUKYND can become a meaningful rare disease franchise across thalassemia and other hematologic disorders, eventually supporting a path toward smaller losses. The UAE approval reinforces Agios’s ex US expansion story but does not change the fact that the key near term catalyst remains execution of broader thalassemia launches, while the biggest risk is still the company’s dependence on PYRUKYND amid ongoing high R&D and SG&A spending. The UAE decision connects directly to Agios’s broader ex US rollout, including the earlier Saudi Arabia approval supported by NewBridge Pharmaceuticals. Together, these steps show how the Gulf Cooperation Council partnership can gradually build a commercial footprint outside the U.S. While still early in revenue contribution, progress in the GCC region sits alongside upcoming U.S. and European thalassemia launches as part of the same catalyst cluster investors are watching. However, investors should also recognize that growing focus on hepatocellular injury and potential label restrictions could materially affect PYRUKYND’s long term commercial profile and... Read the full narrative on Agios Pharmaceuticals (it's free!)Agios Pharmaceuticals' narrative projects $416.9 million revenue and $67.0 million earnings by 2028.Uncover how Agios Pharmaceuticals' forecasts yield a $38.88 fair value, a 36% upside to its current price.Exploring Other PerspectivesAGIO 1-Year Stock Price Chart Before this UAE approval, the most cautious analysts were assuming roughly US$225.6 million of 2028 revenue and a PE near 75x, highlighting how much more pessimistic they were about PYRUKYND’s concentration risk and how new data or approvals like this could eventually shift those expectations in either direction.Explore 2 other fair value estimates on Agios Pharmaceuticals - why the stock might be worth over 7x more than the current price!Reach Your Own ConclusionDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Agios Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.Our free Agios Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Agios Pharmaceuticals' overall financial health at a glance.Curious About Other Options?Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616539224","isCrawlerRequest":true}